Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.